More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds; To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says

Taking stock of the drug industry, from the lab to the medicine chest

November 15, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds The findings add to concerns that drug companies sometimes play fast and loose in order to secure patents to provide or extend monopolies By Ed Silverman STAT+ | To get things done fast at FDA: 'Don't tell anybody,' cancer chief says The Food and Drug Administration's top cancer drug regulator doesn't always ask for permission before taking on big initiatives. By John Wilkerson STAT+ | Life scientists' flight to biotech labs stalls important academic research Academic researchers ditching postdoctoral research in favor of biotech labs. The pace of scientific exodus from academia is raising concern. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser